Dhvanit Rajdeep
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dhvanit Rajdeep has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Sohaima Kamal
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
2 shared publications - Taha Alam
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
2 shared publications - Abdul Rehman
Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan
1 shared publication - Alisha Ahmed
Department of Medicine Jinnah Sindh Medical University Karachi Pakistan
1 shared publication - Aneezeh Khatri
Crisis Text Line
1 shared publication - Areesha Nawaz
Dow University of Health Sciences, Karachi, Pakistan.
1 shared publication
Latest Publications
- Open Access
- 14 August 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (8)
Temporal Trends in Mortality Due to Ischemic Heart Disease and Cardiac Arrhythmias in the United States From 1999 to 2023
Background: Ischemic heart disease (IHD) remains a leading cause of mortality in the United States, while arrhythmia‐related deaths are increasing. However, long‐term mortality trends involving both conditions remain unclear. Methods: We utilized the CDC WONDER Multiple Cause‐of‐Death database to obtain records from 1999 to 2023, targeting US adults aged ≥ 25 years. Deaths involving IHD and arrhythmias were assessed. Age‐adjusted mortality rates (AAMR) were calculated and stratified by gender, age, ethnicity, census region, and urbanization. Results: A total of 1 795 918 deaths were attributed to both IHD and cardiac arrhythmias between 1999 and 2023. The AAMR declined from 41.97 (95% CI: 41.66−42.27) in 1999 to 32.73 (95% CI: 32.51−32.94) in 2023, representing an overall decrease of 22% (AAPC −0.99). Men had higher AAMRs compared to women (45.0 [95% CI: 44.6−45.5] vs. 23.4 [95% CI: 23.2−23.7]). The highest mortality rate was observed among NH White individuals (AAMR: 34.8; 95% CI: 34.5−35.0), while the lowest was among NH Asian or Pacific Islanders (AAMR: 16.5; 95% CI: 15.6−17.5). Older adults exhibited the higher AAMRs (144.74; 95% CI: 143.60−145.88) compared to younger cohorts. An increased death burden was observed in non‐metropolitan (AAMR: 37.1; 95% CI: 36.5−37.8) and Midwest regions (35.5; 95% CI: 34.9−36.0). The majority of the deaths occurred in inpatient facilities (34.7%). Conclusions: Although IHD–arrhythmia mortality declined between 1999 and 2023, substantial disparities persisted across demographic and geographic subgroups, highlighting the need for targeted public health interventions.
- 14 August 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (8)
Open AccessTemporal Trends in Mortality Due to Ischemic Heart Disease and Cardiac Arrhythmias in the United States From 1999 to 2023
Background: Ischemic heart disease (IHD) remains a leading cause of mortality in the United States, while arrhythmia‐related deaths are increasing. However, long‐term mortality trends involving both conditions remain unclear. Methods: We utilized the CDC WONDER Multiple Cause‐of‐Death database to obtain records from 1999 to 2023, targeting US adults aged ≥ 25 years. Deaths involving IHD and arrhythmias were assessed. Age‐adjusted mortality rates (AAMR) were calculated and stratified by gender, age, ethnicity, census region, and urbanization. Results: A total of 1 795 918 deaths were attributed to both IHD and cardiac arrhythmias between 1999 and 2023. The AAMR declined from 41.97 (95% CI: 41.66−42.27) in 1999 to 32.73 (95% CI: 32.51−32.94) in 2023, representing an overall decrease of 22% (AAPC −0.99). Men had higher AAMRs compared to women (45.0 [95% CI: 44.6−45.5] vs. 23.4 [95% CI: 23.2−23.7]). The highest mortality rate was observed among NH White individuals (AAMR: 34.8; 95% CI: 34.5−35.0), while the lowest was among NH Asian or Pacific Islanders (AAMR: 16.5; 95% CI: 15.6−17.5). Older adults exhibited the higher AAMRs (144.74; 95% CI: 143.60−145.88) compared to younger cohorts. An increased death burden was observed in non‐metropolitan (AAMR: 37.1; 95% CI: 36.5−37.8) and Midwest regions (35.5; 95% CI: 34.9−36.0). The majority of the deaths occurred in inpatient facilities (34.7%). Conclusions: Although IHD–arrhythmia mortality declined between 1999 and 2023, substantial disparities persisted across demographic and geographic subgroups, highlighting the need for targeted public health interventions.
- 4 May 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 111 (4) , 1850-1861
Trends in Alzheimer's disease mortality with metabolic syndrome–related conditions among older adults in the United States, 1999–2020
Background: Alzheimer's disease (AD) among patients with metabolic syndrome-related conditions is a global threat, contributing significantly to escalating mortality and economic burden. They demonstrate analogous pathophysiologies and risk determinants, highlighting the necessity for addressing this critical issue. Objective: This study analyzed demographic trends and disparities of AD with metabolic syndrome-related conditions among patients aged 75 and above from 1999 to 2020. Methods: This study examined the death certificates sourced from the CDC-WONDER database from 1999 to 2020, to analyze age-adjusted mortality rates (AAMRs) per 100,000 population. The Joinpoint regression model was used to assess trends in overall demographics, geographic, and place-of-death variables. Results: There were 2,355,233 deaths documented with AD listed as the underlying cause of death among older adults (aged ≥75), out of which 444,488 deaths were related to metabolic syndrome-related conditions from 1999 to 2020. The AAMR rose substantially from 36.48 in 1999 to 157.93 in 2020. Women consistently had higher AAMRs than males (females: 107.79, males: 79.02). Non-Hispanic African Americans (121.65) showed the highest mortality rates among all racial groups. However, from 1999 to the early to mid-2000s, all races highlighted a sharp peak in mortality rates. Striking geographical disparities were noted, with Mississippi in the top 90 th percentile and Massachusetts in the lower 10 th percentile. Conclusions: This study reveals the demographic and geographic variations in mortality rates, highlighting the modalities of interventions and the need for equitable healthcare access.
- 4 May 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 111 (4) , 1850-1861
Trends in Alzheimer's disease mortality with metabolic syndrome–related conditions among older adults in the United States, 1999–2020
Background: Alzheimer's disease (AD) among patients with metabolic syndrome-related conditions is a global threat, contributing significantly to escalating mortality and economic burden. They demonstrate analogous pathophysiologies and risk determinants, highlighting the necessity for addressing this critical issue. Objective: This study analyzed demographic trends and disparities of AD with metabolic syndrome-related conditions among patients aged 75 and above from 1999 to 2020. Methods: This study examined the death certificates sourced from the CDC-WONDER database from 1999 to 2020, to analyze age-adjusted mortality rates (AAMRs) per 100,000 population. The Joinpoint regression model was used to assess trends in overall demographics, geographic, and place-of-death variables. Results: There were 2,355,233 deaths documented with AD listed as the underlying cause of death among older adults (aged ≥75), out of which 444,488 deaths were related to metabolic syndrome-related conditions from 1999 to 2020. The AAMR rose substantially from 36.48 in 1999 to 157.93 in 2020. Women consistently had higher AAMRs than males (females: 107.79, males: 79.02). Non-Hispanic African Americans (121.65) showed the highest mortality rates among all racial groups. However, from 1999 to the early to mid-2000s, all races highlighted a sharp peak in mortality rates. Striking geographical disparities were noted, with Mississippi in the top 90 th percentile and Massachusetts in the lower 10 th percentile. Conclusions: This study reveals the demographic and geographic variations in mortality rates, highlighting the modalities of interventions and the need for equitable healthcare access.
- Open Access
- 4 May 2026
- Published by Georg Thieme Verlag KG in Asian Journal of Neurosurgery
- Vol. 21 (04) , 666-677
Advances in Microsurgical Clipping for Intracranial Aneurysms: A Narrative Review of Intraoperative Technologies and Clinical Outcomes
Intracranial aneurysms carry a life-threatening risk of subarachnoid hemorrhage, and the comparative roles of microsurgical clipping and endovascular coiling continue to evolve alongside rapid technological advancement. This narrative review synthesizes contemporary evidence on microsurgical clipping for cerebral aneurysms, evaluating intraoperative adjunctive technologies, location-specific surgical strategies, clinical outcomes, and emerging future directions. A structured literature search was conducted across PubMed/MEDLINE, Scopus, and Google Scholar for peer-reviewed studies published between 2000 and 2025. Following systematic deduplication and eligibility screening, 55 studies were included in a thematic narrative synthesis. Microsurgical clipping achieves complete aneurysm occlusion in 95 to 99% of cases, with durable long-term results and low retreatment rates. Intraoperative adjuncts, particularly indocyanine green videoangiography and robotic-assisted platforms, have demonstrably reduced ischemic complications. Endovascular coiling offers comparable procedural safety for small-necked aneurysms and facilitates faster short-term recovery; however, recanalization affects a significant proportion of large or wide-necked lesions. Treatment selection is primarily determined by aneurysm morphology, anatomical location, patient comorbidities, and institutional expertise rather than rigid algorithmic criteria. Augmented reality navigation and artificial intelligence-assisted clip positioning represent the most promising emerging technologies for surgical precision and resident training. Microsurgical clipping remains the definitive treatment for intracranial aneurysms requiring long-term occlusion security. Optimal management must integrate individual aneurysm architecture and patient physiology rather than rely on a single-modality treatment algorithm.
- 4 May 2026
- Published by Georg Thieme Verlag KG in Asian Journal of Neurosurgery
- Vol. 21 (04) , 666-677
Open AccessAdvances in Microsurgical Clipping for Intracranial Aneurysms: A Narrative Review of Intraoperative Technologies and Clinical Outcomes
Intracranial aneurysms carry a life-threatening risk of subarachnoid hemorrhage, and the comparative roles of microsurgical clipping and endovascular coiling continue to evolve alongside rapid technological advancement. This narrative review synthesizes contemporary evidence on microsurgical clipping for cerebral aneurysms, evaluating intraoperative adjunctive technologies, location-specific surgical strategies, clinical outcomes, and emerging future directions. A structured literature search was conducted across PubMed/MEDLINE, Scopus, and Google Scholar for peer-reviewed studies published between 2000 and 2025. Following systematic deduplication and eligibility screening, 55 studies were included in a thematic narrative synthesis. Microsurgical clipping achieves complete aneurysm occlusion in 95 to 99% of cases, with durable long-term results and low retreatment rates. Intraoperative adjuncts, particularly indocyanine green videoangiography and robotic-assisted platforms, have demonstrably reduced ischemic complications. Endovascular coiling offers comparable procedural safety for small-necked aneurysms and facilitates faster short-term recovery; however, recanalization affects a significant proportion of large or wide-necked lesions. Treatment selection is primarily determined by aneurysm morphology, anatomical location, patient comorbidities, and institutional expertise rather than rigid algorithmic criteria. Augmented reality navigation and artificial intelligence-assisted clip positioning represent the most promising emerging technologies for surgical precision and resident training. Microsurgical clipping remains the definitive treatment for intracranial aneurysms requiring long-term occlusion security. Optimal management must integrate individual aneurysm architecture and patient physiology rather than rely on a single-modality treatment algorithm.
- 20 April 2026
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
Efficacy of Fibroblast Growth Factor Receptor Inhibitors (FGFRi) in Locally Advanced or Metastatic Cholangiocarcinoma With FGFR Fusions or Rearrangements
Objectives: The efficacy of various FGFR inhibitors (FGFRi) has been reported for advanced cholangiocarcinoma patients harboring FGFR fusion genes or rearrangements. However, the pooled efficacy of FGFRi is still lacking. Methods: PubMed, Cochrane, and Embase databases were systematically searched from inception to Jan 2026 for studies evaluating the efficacy of FGFRi in advanced cholangiocarcinoma patients previously treated with chemotherapy. The primary outcomes were the objective response rate, disease control rate, progression-free survival, and overall survival. Secondary outcomes included safety parameters. A proportional meta-analysis was performed using a random-effects model.Heterogeniety was assessed using I 2 statistics. Results: Eight studies with 463 patients were included. In the pooled analysis, the objective response rate was 40.4% (n=171/463; 95% CI: 31.64%-49.81%), and the disease control rate was 92.48% (n=368/435; 95% CI: 81.68%-98.72%). Progression-free survival was 64.3% (n=164/255; 95% CI: 58.24%-69.96%) and 37.33% (n=84/255; 95% CI: 31.26%-43.84%) at 6 and 12 months, respectively. Overall survival rates were 91.45% (n=139/152; 95% CI: 85.83%-94.97%) and 70.67% (n=159/225; 95% CI: 64.39%-76.25%) at 6 and 12 months, respectively. The common adverse events were hyperphosphatemia (75.4%), alopecia (44.53%), stomatitis (33.20%), diarrhea (32.15%), fatigue (33.64%), dry eyes (25.20%), nail discolouration (17.38%), ALT elevation (14.53%), and AST elevation (16.93%). Conclusions: Our analysis suggests that FGFR alteration testing and the use of FGFRi as an effective alternative option in advanced cholangiocarcinoma patients previously treated with chemotherapy.
- 20 April 2026
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
Efficacy of Fibroblast Growth Factor Receptor Inhibitors (FGFRi) in Locally Advanced or Metastatic Cholangiocarcinoma With FGFR Fusions or Rearrangements
Objectives: The efficacy of various FGFR inhibitors (FGFRi) has been reported for advanced cholangiocarcinoma patients harboring FGFR fusion genes or rearrangements. However, the pooled efficacy of FGFRi is still lacking. Methods: PubMed, Cochrane, and Embase databases were systematically searched from inception to Jan 2026 for studies evaluating the efficacy of FGFRi in advanced cholangiocarcinoma patients previously treated with chemotherapy. The primary outcomes were the objective response rate, disease control rate, progression-free survival, and overall survival. Secondary outcomes included safety parameters. A proportional meta-analysis was performed using a random-effects model.Heterogeniety was assessed using I 2 statistics. Results: Eight studies with 463 patients were included. In the pooled analysis, the objective response rate was 40.4% (n=171/463; 95% CI: 31.64%-49.81%), and the disease control rate was 92.48% (n=368/435; 95% CI: 81.68%-98.72%). Progression-free survival was 64.3% (n=164/255; 95% CI: 58.24%-69.96%) and 37.33% (n=84/255; 95% CI: 31.26%-43.84%) at 6 and 12 months, respectively. Overall survival rates were 91.45% (n=139/152; 95% CI: 85.83%-94.97%) and 70.67% (n=159/225; 95% CI: 64.39%-76.25%) at 6 and 12 months, respectively. The common adverse events were hyperphosphatemia (75.4%), alopecia (44.53%), stomatitis (33.20%), diarrhea (32.15%), fatigue (33.64%), dry eyes (25.20%), nail discolouration (17.38%), ALT elevation (14.53%), and AST elevation (16.93%). Conclusions: Our analysis suggests that FGFR alteration testing and the use of FGFRi as an effective alternative option in advanced cholangiocarcinoma patients previously treated with chemotherapy.